Table 2 Clinicopathological features of tumor-induced AP in different sites
From: Clinical characteristic and pathogenesis of tumor-induced acute pancreatitis: a predictive model
Variables | Pancreas N = 73 | Ampulla N = 13 | Biliary tract N = 14 |  | P |
|---|---|---|---|---|---|
Age (year) | 57.15 ± 11.52 | 54.31 ± 8.71 | 56.36 ± 10.70 | F = 0.369 | 0.693 |
Sex |  |  |  | χ2 = 0.16 | 0.945 |
  Male | 47 (64.4%) | 9 (69.2%) | 9 (64.3%) |  |  |
  Female | 26 (35.6%) | 4 (30.8%) | 5 (35.7%) |  |  |
Severity of pancreatitis |  |  |  | χ2 = 0.801 | 0.747 |
  Mild | 66 (90.4%) | 11 (84.6%) | 13 (92.9%) |  |  |
  Moderate severe/severe | 7 (9.6%) | 2 (15.4%) | 1 (7.1%) |  |  |
Recurrent attacks |  |  |  | χ2 = 1.754 | 0.416 |
  No | 28 (38.4%) | 5 (38.5%) | 8 (57.1%) |  |  |
  Yes | 45 (61.6%) | 8 (61.5%) | 6 (42.9%) |  |  |
Pancreatic duct dilation |  |  |  | χ2 = 10.131 | 0.025 |
  No | 16 (21.9%) | 8 (61.5%) | 7 (50.0%) |  |  |
  Yes | 54 (74.0%) | 5 (38.5%) | 7 (50.0%) |  |  |
  Unknown | 3 (4.1%) | 0 | 0 |  |  |
Bile duct dilation |  |  |  | χ2 = 2.662 | 0.633 |
  No | 25 (34.2%) | 7 (53.8%) | 4 (28.6%) |  |  |
  Yes | 46 (63.0%) | 6 (46.2%) | 10 (71.4%) |  |  |
  Unknown | 2 (2.7%) | 0 | 0 |  |  |
Diameter of tumor (cm) | 4.0 (2.3 4.8) | 1.8 (1.5 2.5) | 1.7 (1.5 2.5) | H = 17.602 | 0.000 |
White blood cells (× 109/L) | 5.41 (4.52 7.54) | 5.91 (4.98 7.15) | 7.53 (5.67 8.03) | H = 2.451 | 0.294 |
Hemoglobin (g/L) | 127.02 ± 15.06 | 123.74 ± 20.10 | 125.06 ± 14.55 | F = 0.264 | 0.768 |
Neutrophilic granulocyte percentage (%) | 66.54 ± 11.68 | 58.25 ± 22.74 | 65.22 ± 10.04 | F = 1.892 | 0.157 |
Hematocrit value | 0.386 ± 0.044 | 0.370 ± 0.060 | 0.372 ± 0.047 | F = 1.007 | 0.369 |
Amylase (U/L) | 138.0 (77.5 234.5) | 166.0 (72.0 949.0) | 245.0 (48.0 528.0) | H = 1.981 | 0.371 |
Lipase (U/L) | 303.00 (205.10 862.20) | 275.35 (131.55 1434.28) | 309.15 (137.63 1165.00) | H = 0.250 | 0.883 |
Serum glucose (mmol/L) | 6.03 (4.98 7.89) | 4.64 (4.19 6.01) | 6.20 (5.02 10.29) | H = 4.873 | 0.087 |
Serum calcium (mmol/L) | 2.30 (2.24 2.35) | 2.22 (2.13 2.44) | 2.23 (2.09 2.32) | H = 5.651 | 0.059 |
Albumin (g/L) | 40.03 ± 4.23 | 41.42 ± 8.92 | 36.05 ± 4.42 | F = 4.506 | 0.014 |
Direct bilirubin (μmol/L) | 8.15 (4.16 110.60) | 6.75 (3.63 49.18) | 26.40 (6.20 137.95) | H = 2.035 | 0.362 |
Indirect bilirubin (μmol/L) | 7.35 (4.38 18.70) | 4.40 (2.80 9.20) | 5.80 (2.85 20.20) | H = 3.793 | 0.15 |
CEA (ng/ml) | 4.06 (2.11 8.50) | 1.48 (0.68 2.39) | 2.75 (1.14 5.37) | H = 12.822 | 0.002 |
CA125 (U/ml) | 23.47 (15.45 91.22) | 38.30 (13.18 272.19) | 23.15 (8.93 43.65) | H = 1.800 | 0.407 |
CA199 (U/ml) | 193.30 (48.12 1601.50) | 69.83 (6.86 322.25) | 131.00 (22.64 411.00) | H = 5.258 | 0.072 |
Stage |  |  |  | χ2 = 34.034 | 0.000 |
  I | 17 (23.3%) | 3 (23.1%) | 1 (7.1%) |  |  |
  II | 10 (13.7%) | 1 (7.7%) | 6 (42.9%) |  |  |
  III | 19 (26.0%) | 0 | 3 (21.4%) |  |  |
  IV | 27 (37.0%) | 3 (23.1%) | 2 (14.3%) |  |  |